Palliativausflüge – eine Möglichkeit der Integration von Palliativpatienten in unsere Gesellschaft - Online ZFA

Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Florian Kaiser(University of Applied Sciences Landshut), Tanja Kraus(Medical University of Graz), Daniela Utke, Ana Hoffmann(University of Applied Sciences Landshut), Felix Kaiser(Universitätsmedizin Göttingen), Ulrich Kaiser(University of Applied Sciences Landshut)

Unknown

July 16, 2018

Cited by 0

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

|The Lancet Oncology|2016|417

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280